What is the UKs Covid-19 drug armoury like amid rising infection levels? – Pharmaceutical Technology

Covid-19 cases in the UK have been picking up since November, with a 39% increase in positive tests in the last seven days alone.

Research shows that the UK is currently in aseasonal spike of Covid-19 infections, with November to April estimated to exhibit high disease activity.

Yet another vaccine was recently added to the UKs fully approved line-up. In October 2023, Novavaxs prototype, Nuvaxovid, gained full marketing authorisation from the MHRA for use in individuals aged 12 and older. An updated vaccine was approved on 24 January. Nuvaxovid was originally greenlit under an emergency use authorisation in 2022.

Novavax CEO John Jacobs said in a 24 January statement announcing full approval of the updated vaccine: Todays MHRA authorisation is recognition of the role our vaccine can have in protecting the British public against Covid-19 this year.

Nuvaxovids inclusion marked the entry of another protein subunit-based vaccine to those available in the UK. It joins long-standing vaccines present from near the beginning of the pandemic, including Pfizer/BioNTechs Comirnaty and Modernas Spikevax, both mRNA vaccines, and Oxford/AstraZenecas viral vector-based Vaxzevria. Janssen and Valneva also have MHRA-approved vaccines.

GSK/Sanofis VidPrevtyn Beta, another protein-based Covid-19 vaccine, was approved for use as a booster in December 2022. HIPRA Human Healths Bimervax was approved in August 2023, becoming the ninth Covid-19 vaccine authorised by the MHRA.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Amidst signs that Covid-19 will become a seasonally spiking virus, the UKs autumn booster programme aims to reduce hospitalisations in those most at risk from severe disease. In the current programme, those aged 65 years and over are eligible, along with those who meet certain criteria.

Omicron BA.2.86 has emerged as the dominant variant throughout winter. While early indications show that it is no more dangerous than other variants, data is limited and the UK Health Security Agency (UKHSA) continues to monitor its circulation.

The UKHSAs chief medical advisor, Professor Susan Hopkins, said in September 2023: The autumn vaccination programme started this month, and this new [variant] data shows once again how important it is that the most vulnerable among us are fully vaccinated in order to receive the greatest possible protection.

The UKHSA reported that last autumns booster programme resulted in patients being 53% less likely to be admitted to hospital with the disease in the 24 weeks following vaccination.

Away from prevention and looking at treatments, more than a million patients will soon gain access to Pfizers antiviral pill Paxlovid (nirmatrelvir/ritonavir). The drug is already recommended to an estimated 3.9 million people who meet certain criteria and, following recommendation by the National Institute of Care and Excellence, a further 1.4 million patients will be eligible.

Alongside Paxlovid, the NHS offers Veklury (remdesivir) from Gilead Sciences and MSDs Lagevrio (molnupiravir). GSK/Vir Biotechs Xevudy (sotrovimab) is a monoclonal antibody given to Covid-19 patients on the NHS who are unsuitable for antivirals.

Approved by the MHRA in December 2021, Paxlovid has been a source of high revenue for Pfizer. The antiviral saw peak global sales in 2022, totalling $18.9bn. Annual sales of the drug have since declined as the number of Covid-19 infections has fallen.

Paxlovid is currently transitioning to the US commercial market. The US commercial price for Paxlovid has been set at nearly $1,400 per five-day course nearly triple what the US Government paid.

Give your business an edge with our leading industry insights.

Here is the original post:

What is the UKs Covid-19 drug armoury like amid rising infection levels? - Pharmaceutical Technology